Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
TATTON: Updated results for patients with EGFR-mutant NSCLC

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.19
Views: 712

Prof Leica Sequist - Massachusetts General Hospital, Boston, USA

Prof Leica Sequist gives a press conference at AACR 2019 about the results from the TATTON study, which examined the combination of osimertinib (a tyrosine kinase inhibitor/TKI) with savolitinib (a MET inhibitor) in patients with EGFR-mutant positive NSCLC.

One arm of the study consisted of patients who had developed MET-resistance after receiving a prior first or second generation EGFR TKI with MET-driven resistance.

The second arm of the study contained a cohort of patients who developed MET-driven resistance after receiving a third generation EGFR TKI.

Prof Sequist reports the response rates, associated side effects, anti-tumour activity and the safety profile of the osimertinib plus savolitinib regimen.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation